��������

The Research and Development team at Incendia Therapeutics is focused on discovering and developing novel anti-cancer therapies that modulate the tumor microenvironment to overcome immune exclusion barriers. They lead the development of groundbreaking programs, such as the PRTH-101 monoclonal antibody, and manage the pipeline of preclinical projects targeting various aspects of the tumor microenvironment. This team integrates proprietary AI technology and precision oncology to enable biomarker-driven patient selection, ensuring that the right medicines reach the right patients.